Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Ateganosine and Cadonilimab in Resectable Hepatocellular Carcinoma
NCT07446257Phase 1Recruiting
- Sponsor
- UT Southwestern Medical Center
- Start
- Sep 2026
- Primary completion
- Sep 2029
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ateganosine and cadonilimab in hepatocellular carcinoma (HCC) (3 arms), sponsored by UT Southwestern Medical Center. Primary endpoint: Incidence of treatment-related delay of surgical resection >28 days. Started Sep 2026; status: recruiting.
02
Drugs
ateganosinecadonilimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07446257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07446257.